Selected projects

Dr. Matías Ávila, the Director of the Hepatology Program: 

"We've identified proteins that can protect liver tissue in acute lesions and we're developing ways in which these proteins can be turned into drugs" 


Access the Hepatology Program

Access the area:  Study of the liver's cellular and molecular response to acute and chronic damage 

Dr. Rubén Pío, Director of the Solid Tumors and Biomarkers Program: 

"Our studies have enabled us to identify markers for early detection, as well as diagnostic, prognostic and predictive markers of response to treatment, which may be useful in the clinical management of patients with lung cancer" 


Access the Solid Tumors and Biomarkers Program.

Access the area: Diagnostic, prognostic, and predictive markers of lung cancer. 

Access the area: New molecular targets in cancer. 

Dr. Felipe Prósper, Director of the Hematology-Oncology Program:

"Interaction between scientists and doctors makes it possible to develop high-impact translational projects that can be personalized for leukemia, lymphoma and myeloma" 


Access the Hematology-Oncology Program.

Access the area: Myeloma and monoclonal gammopathy.

Access the area: Lymphoproliferative disorders. 

Access the area: Acute leukemia.

Access the area: Epigenetic mechanisms of cancer.

Dra. Isabel Pérez-Otaño, Director of the Neuroscience Program:  

"We aim to identify factors that give rise to the neurodegenerative process in order to design new experimental strategies that make it possible to detect and treat the disease in the early stages."  


Access the Neuroscience Program.

Access the area: Molecular and cellular neurobiology.

Access the area: Systems neuroscience.

Access the area: Neurobiology of Parkinson's disease.

Access the area: Neurobiology of Alzheimer's disease. 

Dr. Javier Díez, Director of the Cardiovascular Disease Program: 

"We've identified two new mechanisms involved in fibrosis of the myocardium, which facilitates heart failure, and in brain damage due to atherothrombotic ischemic stroke" 


Access the Cardiovascular Disease Program.

Access the area: Heart failure. 

Access the area: Atherothrombosis.


Dr. Juan José Lasarte, Director of the Immunology and Immunotherapy Program: 

"Our team has developed highly promising immune-regulating molecules and vaccination strategies that have enabled us to carry out clinical trials with excellent results".


Access the Immunology and Immunotherapy Program.

Access the area: Vaccine development.

Access the area: Immune-modulation therapy.

Dra. Gloria González Aseguinolaza, Director of the Gene Therapy and Regulation of Gene Expression Program: 

"We have begun the first clinical trial using gene therapy approved in the European Union for the treatment of acute intermittent porphyria".


Access the Gene Therapy and Regulation of Gene Expression Program.

Access the area: Gene therapy.

Access the area: Regulation of the expression and activity of proteins.

Dr. Felipe Prósper, Director of the Cell Therapy Program:

"Cell therapy is one of the essential pillars of the medicine of the future, thanks to the discovery of induced pluripotent stem cells (iPS) and the consolidation of cell reprogramming" 


Access the Cell Therapy Program.

Access the area: Stem cells and reprogramming, rare diseases.

Access the area: Cardiovascular regenerative medicine.

Access the area: Cell therapy in osteoarticular diseases. 

Access the area: Applications of advanced-therapy products. 

Dr. Julen Oyarzabal, Director of the Molecular Therapies Program:

"Our goal is to discover new molecular therapies that can meet unresolved medical needs, based on new targets and/or mechanisms of action contributed by researchers from the Center for Applied Medical Research (CIMA)". 


Access the Molecular Therapy Program.

Access the area: Aptamers.

Access the area: Peptides. 

Access the area: Small molecules. 


María Victoria Richter Larrea
Avda. Pío XII, 55
31008 Pamplona

(+34) 948 194 700
Ext. 5025

Advantages y benefits

Discover the advantages of collaborating with CIMA research.

See benefits